Table 5.

Multivariate analysis evaluating predictors of non-relapse mortality, disease progression, progression-free survival and overall survival.

Predictor	Non-relapse mortality		Disease progression		Disease-free survival		Overall survival
	HR	P	HR	P	HR	P	HR	P
	(95% CI)		(95% CI)		(95% CI)		(95% CI)
SIRPα
Mismatched	0.7	0.2	0.5*	0.003	0.5*	0.001	0.7	0.1
	(0.4-1.3)		(0.3-0.8)		(0.3-0.8)		(0.5-1.1)
HCT-CI
>3	2.2	0.007	----	---	1.7	0.003	1.9	<0.001
	(1.2-3.8)				(1.2-2.3)		(1.3-2.9)
Age, years
>50	1.8	0.04	----	---	----	---	----	---
	(1.02-3.3)
Conditioning regimen
Myeloablative	----	---	----	---	1.6	0.007	----	---
					(1.1-2.2)
Diagnosis
ALL	----	---	----	---	----	---	2.2	<0.001
							(1.5-3.2)

ALL: acute lymphoblastic leukemia* The protective effect of SIRPα mismatch was limited to diagnoses other than non-Hodgkin’s lymphoma. SIRPα mismatch did not impact the rate of disease progression (HR=1.2, 95% CI 0.6-2.5, P= .5) or progression-free survival (HR=1.1, 95% CI 0.6-1.9, P= .8) in patients with non-Hodgkin’s lymphoma.